Evaluating Joint Support Ingredients in Canine Osteoarthritis

Nutritional Support in Multimodal OA Management

Osteoarthritis (OA) is a common chronic condition requiring a multimodal approach, including weight management, controlled activity, rehabilitation, pharmacologic therapy, and nutritional support.

However, joint health ingredients vary widely in their mechanism, strength of evidence, and clinical relevance across disease stages, making ingredient selection an important part of patient management.

Omega-3 Fatty Acids (EPA + DHA): Inflammatory Modulation

Mechanism
The body is constantly striving to be in balance between inflammation (omega-6s) and anti-inflammation (omega-3s, particularly EPA & DHA). Although dogs and cats need inflammation to heal wounds and fight infection, too much inflammation over time leads to many systemic health conditions and diseases. EPA and DHA help modulate systemic inflammation by:

• Competing with arachidonic acid in cell membranes
• Shifting eicosanoid production toward less pro-inflammatory mediators

Unlike ALA (plant-based omega-3, often found in commercial pet foods), which is poorly converted in dogs and not converted in cats, direct EPA and DHA supplementation is required to meaningfully impact tissue levels.

Clinical Evidence
A prospective, randomized, double-blind, placebo-controlled study by Veterinarian Recommended Solutions demonstrated that EPA+DHA supplementation is associated with:

• Significant improvements in lameness, discomfort, and overall joint scores as soon as day 84
• Earlier improvements in some parameters (e.g., crepitus, joint pain and effusion scores, overall improvement scores) by day 42
• Measurable reductions in fatty acid ARA/(EPA+DHA ratio
• Correlation between improved fatty acid profiles and clinical outcomes

Use Considerations
Best suited for:

• Patients where inflammatory modulation is a primary goal
• For broad health support: Joint Health, Skin & Coat Health, Overall Wellness
• Foundational, long-term support in multimodal care

Green-Lipped Mussel Extract (GLME): Structural Joint Support

Mechanism
Green-lipped mussel extract (GLME), particularly concentrated formulations containing bioactive fractions such as glycoproteins and glycosaminoglycans, is associated with:

• Inhibiting matrix metalloproteinases (MMPs) involved in cartilage breakdown
• Supporting connective tissue and cartilage structure
• Modulation of processes involved in joint degeneration

Notably, extract forms have demonstrated greater biologic activity compared to mussel oil alone. The MMP inhibitory effect of green-lipped mussel extract was shown to be many times greater than that of green-lipped mussel oil.

Clinical Evidence
Data across studies (500+ dogs and cats with OA) demonstrate:

• Improvements in clinical signs of OA when treated with GLME
• Strong safety and tolerability
• Clinical improvements ranging from ~10 days (mild cases) to four weeks or more

Use Considerations
Best suited for:

• Moderate to advanced OA
• Cases requiring cartilage and structural support
• Long-term joint integrity management

Glucosamine: Adjunctive Support with Variable Evidence

Glucosamine is widely used as a cartilage substrate but:

• Typically functions as adjunctive or early-stage support
• Has mixed and inconsistent clinical evidence in OA

While glucosamine at one time was considered the gold standard, available evidence in dogs and cats supports a more limited, adjunctive role in osteoarthritis management.

Timing and Client Expectations

Across nutritional interventions:

• Improvements are gradual and progressive
• Early changes often include comfort and mobility
• Consistent daily use is required to assess response

Therefore when advising your clients, recommending long-term use is appropriate.

Clinical Takeaways

• Omega-3s (EPA + DHA): Supported by controlled clinical studies for improving clinical signs of OA through inflammatory modulation
• Green Lipped Mussel Extract: Targeted support for cartilage and connective tissue, with evidence across multiple studies of dogs and cats
• Glucosamine: Commonly used but less consistently supported by clinical outcomes

A Dual-Pathway Approach

Addressing both inflammation and structural degeneration provides a more comprehensive strategy for OA management. Combining omega-3 fatty acids with green-lipped mussel extract supports complementary mechanisms within a multimodal plan.

👉 Learn more about TruBenefits® Omega and TruBenefits® Osteo at vet.vrshealth.com[DS1]  or through your VRS representative. 

👉 Also consider the the iFATs® test from VRS for your hospital - a simple diagnostic blood test to measure the ratio between the pro-inflammatory omega-6 fatty acids and the anti-inflammatory omega-3 fatty acids in your patient’s body.